Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Direct Immunofluorescence Assay testing for H1N1 influenza is unreliable in ICU patients, according to a new study from Stanford University. Multiple methods exist for diagnosing influenza, but data on the utility and accuracy of these tests for H1N1 are still emerging, given the relatively recent onset of the epidemic.
NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.
Connecticut waterways may be safer from biomedical waste, thanks to an innovative Community Economic Development Fund small business loan guarantee program. CEDF, with loan-program partners, Connecticut's Department of Economic and Community and the City of West Haven have guaranteed a small business loan to a West Haven company that stems improper disposal of needles and prescription drugs.
As the 193 WHO member states gather at next week's World Health Assembly (WHA) "a draft global code of practice on the international recruitment of health personnel will be on the agenda. Negotiation and adoption of a WHO code of practice is an unprecedented opportunity to advance global consensus to address the critical challenges of migration of health workers and its effect on health systems worldwide," the authors of a Lancet Comment write.
BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.
NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.
Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
Novavax, Inc. announces the first report of a vaccine protecting ferrets against the 2009 pandemic H1N1 virus has been published in the journal Vaccine May 12, 2010 online issue.
Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.
Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.
NanoViricides, Inc., announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering. The registered shelf offering became effective on April 29, 2010.
More Americans die annually from invasive methicillin-resistant Staphylococcus aureus infections than from HIV/AIDS, H1N1 influenza and Parkinson's disease, yet the United States and many other countries' health officials continue to ignore the global crisis.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.
As H1N1 began to emerge in April 2009, HealthMap - an automated online disease tracking and mapping tool created by researchers in the Informatics Program at Children's Hospital Boston - was already collecting information about the virus and plotting that information on a map of the globe, creating a freely available, real-time, digestible display of the outbreak.
"A year after the H1N1 [swine] flu first appeared, the World Health Organization has issued perhaps the most comprehensive report on the pandemic's activity to date," HealthDay News/Bloomberg BusinessWeek reports (Gardner, 5/5).
Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.
CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.
In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.
Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.